HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Heiner Wedemeyer Selected Research

Interferon-alpha (Interferon Alfa)

1/2022HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta.
1/2020Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
1/2019Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
1/2017Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
1/2016Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
11/2014Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review.
11/2014Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
1/2014Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
1/2014PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
6/2013Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Heiner Wedemeyer Research Topics

Disease

169Infections
11/2022 - 02/2002
63Chronic Hepatitis C
06/2022 - 02/2002
63Hepatitis C
01/2022 - 07/2004
58Fibrosis (Cirrhosis)
12/2022 - 11/2004
34Chronic Hepatitis B
11/2022 - 10/2007
30Liver Diseases (Liver Disease)
01/2022 - 01/2007
30Hepatocellular Carcinoma (Hepatoma)
07/2021 - 12/2004
27Hepatitis B
11/2022 - 01/2003
25Hepatitis D
01/2022 - 03/2009
22Liver Cirrhosis (Hepatic Cirrhosis)
04/2022 - 11/2004
22Hepatitis
02/2022 - 01/2005
18Chronic Hepatitis (Chronic Active Hepatitis)
11/2022 - 01/2010
17Neoplasms (Cancer)
05/2022 - 03/2005
15Virus Diseases (Viral Diseases)
01/2021 - 02/2002
10Disease Progression
01/2022 - 10/2008
10Viremia
10/2020 - 01/2008
9Inflammation (Inflammations)
12/2022 - 01/2010
9Coinfection
07/2021 - 03/2007
8Ascites
04/2022 - 01/2017
8Autoimmune Hepatitis
01/2022 - 01/2011
7Hepatitis E
01/2022 - 01/2011
7Non-alcoholic Fatty Liver Disease
01/2021 - 12/2016
7Liver Failure
01/2021 - 11/2007
6End Stage Liver Disease
12/2020 - 03/2008
5Hemorrhage
01/2022 - 09/2014
5Persistent Infection
01/2022 - 02/2006
5HIV Infections (HIV Infection)
01/2020 - 10/2011
4Portal Hypertension
04/2022 - 11/2015
4Communicable Diseases (Infectious Diseases)
01/2021 - 12/2012
4Reinfection
11/2019 - 10/2006
4Hepatitis A (Hepatitis, Infectious)
11/2018 - 12/2006
4Chronic Hepatitis D
01/2016 - 03/2010
3Wounds and Injuries (Trauma)
12/2022 - 09/2018
3Thrombocytopenia (Thrombopenia)
01/2022 - 09/2014
3Sclerosing Cholangitis
06/2021 - 01/2011
3Liver Neoplasms (Liver Cancer)
01/2021 - 01/2017
3Diabetes Mellitus
07/2019 - 06/2008

Drug/Important Bio-Agent (IBA)

84Antiviral Agents (Antivirals)IBA
06/2022 - 11/2004
61InterferonsIBA
01/2022 - 02/2002
52RNA (Ribonucleic Acid)IBA
01/2022 - 01/2005
51Ribavirin (Virazole)FDA LinkGeneric
01/2022 - 02/2002
33Hepatitis B Surface Antigens (HBsAg)FDA Link
11/2022 - 01/2008
24DNA (Deoxyribonucleic Acid)IBA
01/2021 - 10/2007
21Interferon-alpha (Interferon Alfa)IBA
01/2022 - 02/2002
17AntigensIBA
11/2022 - 10/2007
17VaccinesIBA
05/2022 - 10/2006
16Biomarkers (Surrogate Marker)IBA
11/2022 - 11/2011
14Proteins (Proteins, Gene)FDA Link
01/2022 - 07/2004
13Hepatitis B e AntigensIBA
11/2022 - 01/2008
13CytokinesIBA
01/2022 - 10/2011
13AntibodiesIBA
01/2022 - 01/2009
13Pharmaceutical PreparationsIBA
03/2021 - 05/2008
11Peptides (Polypeptides)IBA
10/2019 - 09/2007
10peginterferon alfa-2a (Pegasys)FDA Link
01/2020 - 01/2011
9BilirubinIBA
12/2021 - 03/2008
9Protease Inhibitors (Protease Inhibitor)IBA
01/2021 - 04/2005
8AlbuminsIBA
12/2021 - 08/2014
8telaprevirIBA
01/2016 - 01/2013
7Alanine Transaminase (SGPT)IBA
01/2022 - 01/2008
7glecaprevir and pibrentasvirIBA
01/2022 - 01/2018
7SofosbuvirIBA
01/2020 - 01/2014
7N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
01/2016 - 02/2009
6Surface Antigens (Surface Antigen)IBA
01/2018 - 01/2008
6entecavirFDA Link
11/2016 - 04/2010
6adefovirIBA
12/2015 - 01/2011
5EnzymesIBA
12/2022 - 09/2014
5Immunoglobulins (Immunoglobulin)IBA
12/2021 - 10/2006
5Ritonavir (Norvir)FDA Link
11/2018 - 05/2014
5dasabuvirIBA
11/2018 - 05/2014
5ombitasvirIBA
11/2018 - 05/2014
5paritaprevirIBA
11/2018 - 05/2014
4Aspartate Aminotransferases (Aspartate Transaminase)IBA
12/2021 - 01/2020
4EpitopesIBA
10/2019 - 12/2009
4Tenofovir (Viread)FDA Link
01/2019 - 01/2010
4Viral RNAIBA
01/2018 - 11/2004
4NucleosidesIBA
06/2013 - 10/2006
3Norepinephrine (Noradrenaline)FDA LinkGeneric
12/2022 - 11/2021
3bulevirtideIBA
11/2022 - 01/2019
3Immunoglobulin G (IgG)IBA
01/2022 - 01/2010
3sofosbuvir drug combination ledipasvirIBA
01/2022 - 10/2016
3Interleukin-17 (Interleukin 17)IBA
01/2021 - 10/2019
3LigandsIBA
01/2021 - 05/2010
3InterleukinsIBA
01/2021 - 10/2011
3Messenger RNA (mRNA)IBA
01/2020 - 05/2010
3Transaminases (Aminotransferases)IBA
01/2020 - 09/2018
3daclatasvirIBA
01/2018 - 02/2015
3Interferon Type IIBA
01/2015 - 07/2009
3Hepatitis delta Antigens (HDAg)IBA
09/2014 - 01/2011

Therapy/Procedure

124Therapeutics
12/2022 - 12/2002
36Liver Transplantation
12/2022 - 10/2006
8Duration of Therapy
01/2020 - 10/2006
7Transplantation
01/2021 - 01/2010
6Immunotherapy
01/2020 - 03/2005
5Drug Therapy (Chemotherapy)
01/2018 - 10/2010
4Transjugular Intrahepatic Portasystemic Shunt
04/2022 - 01/2018
4Surgical Portasystemic Shunt (Portosystemic Shunt)
04/2022 - 05/2017
4Aftercare (After-Treatment)
01/2021 - 12/2015
4Opiate Substitution Treatment
01/2019 - 07/2013
3Contraindications
01/2022 - 05/2017
3Drug Tapering
06/2015 - 11/2013